T. Rowe Price Associates’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $478K | Buy |
27,391
+5,632
| +26% | +$98.3K | ﹤0.01% | 2324 |
|
|
2025
Q1 | $274K | Buy |
21,759
+1,841
| +9% | +$23.2K | ﹤0.01% | 2512 |
|
|
2024
Q4 | $211K | Sell |
19,918
-442,601
| -96% | -$4.69M | ﹤0.01% | 2645 |
|
|
2024
Q3 | $6.71M | Buy |
462,519
+446,799
| +2,842% | +$6.48M | ﹤0.01% | 1222 |
|
|
2024
Q2 | $134K | Buy |
+15,720
| New | +$134K | ﹤0.01% | 2697 |
|
|
2023
Q3 | – | Sell |
-16,537
| Closed | -$111K | – | 2907 |
|
|
2023
Q2 | $111K | Buy |
16,537
+4,936
| +43% | +$33.1K | ﹤0.01% | 2677 |
|
|
2023
Q1 | $76K | Buy |
+11,601
| New | +$76K | ﹤0.01% | 2732 |
|
|
2022
Q4 | – | Sell |
-26,500
| Closed | -$140K | – | 2976 |
|
|
2022
Q3 | $140K | Sell |
26,500
-139,700
| -84% | -$738K | ﹤0.01% | 2646 |
|
|
2022
Q2 | $705K | Sell |
166,200
-134,374
| -45% | -$570K | ﹤0.01% | 2058 |
|
|
2022
Q1 | $1.06M | Buy |
300,574
+900
| +0.3% | +$3.16K | ﹤0.01% | 1976 |
|
|
2021
Q4 | $2M | Buy |
+299,674
| New | +$2M | ﹤0.01% | 1711 |
|